- Mechanisms of Neurodegeneration
- Parkin
- PINK1
- FBXO7 - Mitophagy adaptor protein mutated in Parkinson's disease
- ATP13A2 - Lysosomal ATPase mutated in Kufor-Rakeb syndrome - Mitophagy adaptor protein mutated in Parkinson's disease
- ATP13A2 - Lysosomal ATPase mutated in Kufor-Rakeb syndrome
- PubMed — Biomedical literature
- Alzheimer's Disease Neuroimaging Initiative — Research data
- Allen Brain Atlas — Brain gene expression data
- MitoPorto — Mitochondrial disease portal
The study of Mitochondrial Dysfunction And Oxidative Stress In Alzheimer's Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
A study by Li et al. published in Cell (February 2026) revealed a novel link between cancer and AD pathophysiology. The research showed that peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2, providing epidemiological evidence that cancer incidence significantly decreases in AD patients. This finding highlights the importance of the immune system and cross-organ interactions in AD Li et al., 2026.
The liver-brain axis has emerged as a new area of interest following research by Bieri et al. in Cell (March 2026), which demonstrated that the liver-derived exercise factor GPLD1 (glycosylphosphatidylinositol-specific phospholipase D1) reverses aging- and Alzheimer's-related memory loss by targeting brain vasculature. This finding suggests that exercise-induced circulating factors from peripheral organs can have direct therapeutic effects on the brain Bieri et al., 2026.
This section highlights recent publications relevant to this mechanism.
- Human in vitro and rodent in vivo models highlight progressive mitochondrial dysfunction as a starting point of cerebral amyloidosis. (2026 May) - Neurobiology of aging
- ALDH2 activation protects against mutant TOMM40-mediated mitochondrial dysfunction and neurodegeneration in Alzheimer's disease. (2026 Apr 15) - Life sciences
- Postbiotics and the gut-brain axis: A mechanistic review on modulating neuroinflammation and cognitive aging. (2026 Apr) - Journal of neuroimmunology
- The aging gut-glia-immune axis in alzheimer's disease: microbiome-derived mediators of neuroinflammation and therapeutic innovation. (2026 Apr) - GeroScience
- Traumatic brain injury exacerbates mitochondrial dysfunction in APP/PS1 knock-in mice through time-dependent pathways. (2026 Apr) - Experimental neurology
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
[@areagomez]: [Area-Gomez E, et al[^12]: Manczak M, Reddy PH. Abnormal interaction of DRP1 with Amyloid-Beta and phosphorylated tau
[@todkar]: Todkar K, et al. Mitochondria break free: mitochondria-derived vesicles in aging and associated conditions
[@pratic]: Praticò D. Oxidative stress hypothesis in Alzheimer's Disease
[@montine]: Montine TJ, Neely MD, Quinn JF, et al. Lipid peroxidation in aging brain and Alzheimer's Disease
[@smith]: Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ
[@wang]: Wang X, et al. NAD+-boosting agent NMN potently improves mitochondria stress response in AD via ATF4-dependent mitochondrial UPR
[@wu]: Wu J, et al. Cognitive and Alzheimer's Disease biomarker effects of oral nicotinamide riboside supplementation---
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
19 references |
| Replication |
33% |
| Effect Sizes |
25% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 52%
flowchart TD
A["Amyloid-Beta"] --> B["Mitochondrial Import via TOM"]
B --> C["Complex IV Inhibition"]
A --> D["CypD Binding / mPTP Opening"]
D --> E["Ca2+ Dysregulation"]
E --> F["Cytochrome c Release"]
F --> G["Apoptosis"]
H["Hyperphospho-Tau"] --> I["Complex I Inhibition"]
H --> J["DRP1 Activation"]
J --> K["Excessive Fission"]
K --> L["Fragmented Mitochondria"]
L --> M["ROS Generation"]
M --> N["Oxidative DNA/Protein Damage"]
N --> O["Neurodegeneration"]
I --> M
C --> M
flowchart LR
A["Mitochondrial<br/>Damage"] --> B{"Quality<br/>Control"}
B --> C["Mitochondrial<br/>Biogenesis"]
B --> D["Fusion"]
B --> E["Fission"]
B --> F["Mitophagy"]
C --> C1["PGC-1α"]
C --> C2["TFAM"]
C --> C3["mtDNA<br/>Replication"]
D --> D1["OPA1"]
D --> D2["Mfn1/2"]
E --> E1["DRP1"]
E --> E2["FIS1"]
F --> F1["PINK1"]
F --> F2["Parkin"]
F --> F3["Autophagosome"]
style A fill:#ff6b6b,stroke:#333,stroke-width:2px
style B fill:#ffe66d,stroke:#333,stroke-width:2px